Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVACNASDAQ:FHTXNASDAQ:SYRENASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVACCureVac$4.53-2.2%$3.35$2.37▼$5.28$1.02B2.43741,068 shs853,039 shsFHTXFoghorn Therapeutics$4.14-4.2%$3.94$2.94▼$10.25$230.77M3.13141,448 shs388,693 shsSYRESpyre Therapeutics$15.25-1.9%$14.33$10.91▼$40.26$919.21M2.78613,714 shs380,763 shsWVEWave Life Sciences$6.08-2.6%$6.64$4.25▼$16.74$937.14M-0.921.30 million shs1.27 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVACCureVac+4.28%+11.30%+31.16%+49.35%+22.16%FHTXFoghorn Therapeutics+0.47%+4.35%+1.65%-10.93%-23.27%SYRESpyre Therapeutics+3.12%+3.19%+3.53%-21.07%-51.50%WVEWave Life Sciences+3.14%+2.46%-14.99%-40.96%+4.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVACCureVac4.018 of 5 stars3.52.00.04.82.60.01.3FHTXFoghorn Therapeutics2.3224 of 5 stars3.62.00.00.02.51.70.6SYRESpyre Therapeutics2.4902 of 5 stars3.61.00.00.03.02.50.6WVEWave Life Sciences4.3549 of 5 stars3.50.00.04.84.14.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVACCureVac 3.00Buy$11.00142.83% UpsideFHTXFoghorn Therapeutics 3.13Buy$12.13192.87% UpsideSYRESpyre Therapeutics 3.25Buy$53.40250.16% UpsideWVEWave Life Sciences 3.00Buy$21.17248.14% UpsideCurrent Analyst Ratings BreakdownLatest FHTX, CVAC, WVE, and SYRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025CVACCureVacJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$10.005/15/2025FHTXFoghorn TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$9.00 ➝ $9.005/14/2025FHTXFoghorn TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/5/2025SYRESpyre TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$65.004/30/2025CVACCureVacUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$13.00 ➝ $12.004/30/2025FHTXFoghorn TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$9.00 ➝ $9.004/30/2025FHTXFoghorn TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.004/29/2025WVEWave Life SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$10.004/23/2025FHTXFoghorn TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/23/2025FHTXFoghorn TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMkt Outperform$9.004/23/2025FHTXFoghorn TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$9.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVACCureVac$523.70M1.94N/AN/A$2.50 per share1.81FHTXFoghorn Therapeutics$23.50M9.82N/AN/A($1.83) per share-2.26SYRESpyre Therapeutics$890K1,032.82N/AN/A($0.22) per share-69.32WVEWave Life Sciences$104.94M8.93N/AN/A$0.40 per share15.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVACCureVac-$281.58M$0.928.24N/AN/A20.72%21.98%15.72%8/13/2025 (Estimated)FHTXFoghorn Therapeutics-$98.43M-$1.36N/AN/AN/A-357.53%N/A-30.98%8/14/2025 (Estimated)SYRESpyre Therapeutics-$338.79M-$3.77N/AN/AN/AN/A-210.01%-44.40%8/6/2025 (Estimated)WVEWave Life Sciences-$57.51M-$0.84N/AN/AN/A-66.50%-280.57%-52.90%8/14/2025 (Estimated)Latest FHTX, CVAC, WVE, and SYRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q1 2025CVACCureVac-$0.16-$0.24-$0.08-$0.24$4.27 million$0.94 million5/14/2025Q1 2025FHTXFoghorn Therapeutics-$0.30-$0.30N/A-$0.30$4.96 million$5.95 million5/8/2025Q1 2025SYRESpyre Therapeutics-$0.76-$0.74+$0.02-$0.74N/AN/A5/8/2025Q1 2025WVEWave Life Sciences-$0.27-$0.29-$0.02-$0.29$11.65 million$9.18 million4/10/2025Q4 2024CVACCureVac-$0.14-$0.15-$0.01-$0.15$6.40 million$15.44 million3/6/2025Q4 2024FHTXFoghorn Therapeutics-$0.43-$0.30+$0.13-$0.30$8.56 million$2.86 million3/4/2025Q4 2024WVEWave Life Sciences-$0.17$0.17+$0.34$0.17$25.60 million$83.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVACCureVacN/AN/AN/AN/AN/AFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/AWVEWave Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVACCureVac0.056.206.19FHTXFoghorn TherapeuticsN/A4.774.77SYRESpyre TherapeuticsN/A7.327.32WVEWave Life SciencesN/A1.901.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVACCureVac17.26%FHTXFoghorn Therapeutics61.55%SYRESpyre Therapeutics80.39%WVEWave Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipCVACCureVac2.15%FHTXFoghorn Therapeutics7.58%SYRESpyre Therapeutics15.43%WVEWave Life Sciences29.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVACCureVac880224.34 million219.07 millionOptionableFHTXFoghorn Therapeutics12055.74 million50.57 millionOptionableSYRESpyre Therapeutics7360.28 million48.24 millionOptionableWVEWave Life Sciences240154.13 million108.14 millionOptionableFHTX, CVAC, WVE, and SYRE HeadlinesRecent News About These CompaniesWave Life Sciences to Present at 2025 Jefferies Global Healthcare ConferenceMay 29 at 8:30 AM | globenewswire.comWave Life Sciences Ltd. (NASDAQ:WVE) Shares Acquired by Two Sigma Investments LPMay 29 at 3:58 AM | marketbeat.comBank of America Corp DE Acquires 160,820 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE)May 29 at 3:21 AM | marketbeat.comWave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical OfficerMay 28 at 8:00 AM | globenewswire.comPolar Asset Management Partners Inc. Has $6.89 Million Position in Wave Life Sciences Ltd. (NASDAQ:WVE)May 28 at 5:51 AM | marketbeat.com845,830 Shares in Wave Life Sciences Ltd. (NASDAQ:WVE) Purchased by Voloridge Investment Management LLCMay 27 at 4:46 AM | marketbeat.comWave Life Sciences Ltd. (NASDAQ:WVE) Holdings Lifted by Millennium Management LLCMay 25, 2025 | marketbeat.comBNP Paribas Financial Markets Increases Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)May 20, 2025 | marketbeat.comWave Life Sciences Ltd. (NASDAQ:WVE) Receives $21.17 Consensus PT from BrokeragesMay 20, 2025 | americanbankingnews.comWave Life Sciences Ltd. (NASDAQ:WVE) Holdings Increased by Northern Trust CorpMay 19, 2025 | marketbeat.comWave Life Sciences Ltd. (NASDAQ:WVE) Given Average Rating of "Buy" by AnalystsMay 19, 2025 | marketbeat.comPolar Capital Holdings Plc Acquires New Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)May 18, 2025 | marketbeat.comWave Life Sciences Ltd. (NASDAQ:WVE) Shares Bought by D. E. Shaw & Co. Inc.May 17, 2025 | marketbeat.comMPM Bioimpact LLC Raises Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)May 16, 2025 | marketbeat.comFY2025 EPS Estimates for WVE Increased by Cantor FitzgeraldMay 16, 2025 | marketbeat.comMaven Securities LTD Sells 680,000 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE)May 15, 2025 | marketbeat.comB. Riley Has Pessimistic Outlook of WVE FY2029 EarningsMay 14, 2025 | marketbeat.comFY2028 Earnings Estimate for WVE Issued By WedbushMay 14, 2025 | marketbeat.comIs Wave Life Sciences (WVE) the Best Low Priced Biotech Stock to Buy Now?May 13, 2025 | msn.comWave Life Sciences Ltd. (NASDAQ:WVE) Shares Purchased by The Manufacturers Life Insurance CompanyMay 13, 2025 | marketbeat.comAlgert Global LLC Invests $527,000 in Wave Life Sciences Ltd. (NASDAQ:WVE)May 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFHTX, CVAC, WVE, and SYRE Company DescriptionsCureVac NASDAQ:CVAC$4.53 -0.10 (-2.16%) Closing price 04:00 PM EasternExtended Trading$4.55 +0.02 (+0.44%) As of 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Foghorn Therapeutics NASDAQ:FHTX$4.14 -0.18 (-4.17%) Closing price 04:00 PM EasternExtended Trading$4.08 -0.06 (-1.45%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Spyre Therapeutics NASDAQ:SYRE$15.25 -0.30 (-1.93%) Closing price 04:00 PM EasternExtended Trading$14.84 -0.41 (-2.72%) As of 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.Wave Life Sciences NASDAQ:WVE$6.08 -0.16 (-2.56%) Closing price 04:00 PM EasternExtended Trading$6.01 -0.07 (-1.15%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
